Silverback Therapeutics (NASDAQ:SBTX) Shares Down 0.6% – Here’s What Happened

Silverback Therapeutics, Inc. (NASDAQ:SBTX)’s share price was down 0.6% during mid-day trading on Monday . The stock traded as low as $9.05 and last traded at $9.28. Approximately 660,760 shares traded hands during mid-day trading, an increase of 96% from the average daily volume of 337,931 shares. The stock had previously closed at $9.34.

Silverback Therapeutics Trading Down 0.6%

The company has a market cap of $334.62 million, a P/E ratio of -3.83 and a beta of 0.60. The business’s 50 day simple moving average is $10.43 and its 200 day simple moving average is $10.29.

Silverback Therapeutics Company Profile

Silverback Therapeutics, Inc (NASDAQ: SBTX) is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company’s proprietary ImmunoTAC™ (tumor-activated cytokine) platform is designed to harness the innate immune system by conjugating toll-like receptor agonists to tumor-targeting antibodies. This modular approach aims to deliver immune-activating molecules directly to the tumor microenvironment, potentially improving the safety and efficacy profiles of existing immunomodulatory therapies.

Silverback’s pipeline includes multiple antibody-TLR agonist conjugates in early-phase clinical trials, each directed against distinct tumor-associated antigens.